Eric Westman

List of Publications by Year
in descending order

200 papers	11,654 citations	25031 57 h-index	37202 96 g-index
218 all docs	218 docs citations	218 times ranked	16121 citing authors

#	Article	IF	Citations
1	Harmonizing neuropsychological assessment for mild neurocognitive disorders in Europe. Alzheimer's and Dementia, 2022, 18, 29-42.	0.8	24
2	MRI-derived brain age as a biomarker of ageing in rats: validation using a healthy lifestyle intervention. Neurobiology of Aging, 2022, 109, 204-215.	3.1	6
3	Parsing heterogeneity within dementia with Lewy bodies using clustering of biological, clinical, and demographic data. Alzheimer's Research and Therapy, 2022, 14, 14.	6.2	10
4	Plasma and CSF NfL are differentially associated with biomarker evidence of neurodegeneration in a communityâ€based sample of 70â€yearâ€olds. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2022, 14, e12295.	2.4	11
5	The protective gene dose effect of the APOEÎµ2 allele on gray matter volume in cognitively unimpaired individuals. Alzheimer's and Dementia, 2022, 18, 1383-1395.	0.8	13
6	Normal Olfactory Functional Connectivity Despite Lifelong Absence of Olfactory Experiences. Cerebral Cortex, 2021, 31, 159-168.	2.9	13
7	Sex differences in CSF biomarkers for neurodegeneration and bloodâ€brain barrier integrity. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2021, 13, e12141.	2.4	9
8	ANMerge: A Comprehensive and Accessible Alzheimerâ€™s Disease Patient-Level Dataset. Journal of Alzheimer's Disease, 2021, 79, 423-431.	2.6	18
9	Comparing different approaches for operationalizing subjective cognitive decline: impact on syndromic and biomarker profiles. Scientific Reports, 2021, 11, 4356.	3.3	17
10	Data-driven FDG-PET subtypes of Alzheimerâ€™s disease-related neurodegeneration. Alzheimer's Research and Therapy, 2021, 13, 49.	6.2	44
11	Cortical Networks Underpinning Compensation of Verbal Fluency in Normal Aging. Cerebral Cortex, 2021, 31, 3832-3845.	2.9	12
12	Cognitive dedifferentiation as a function of cognitive impairment in the ADNI and MemClin cohorts. Aging, 2021, 13, 13430-13442.	3.1	2
13	Inter-Cohort Validation of SuStaIn Model for Alzheimerâ€™s Disease. Frontiers in Big Data, 2021, 4, 661110.	2.9	15
14	Effects of amyloid pathology and the APOE Îµ4 allele on the association between cerebrospinal fluid AÎ²38 and AÎ²40 and brain morphology in cognitively normal 70-years-olds. Neurobiology of Aging, 2021, 101, 1-12.	3.1	7
15	The Use of Magnetic Resonance Imaging Techniques in Assessing the Effects of Alcohol Consumption and Heavy Drinking on the Adolescent Brain: A Scoping Review Protocol. Brain Sciences, 2021, 11, 764.	2.3	0
16	Cognitive changes and neural correlates after oral rehabilitation procedures in older adults: a protocol for an interventional study. BMC Oral Health, 2021, 21, 297.	2.3	5
17	Cerebrovascular Disease and Depressive Symptomatology in Individuals With Subjective Cognitive Decline: A Community-Based Study. Frontiers in Aging Neuroscience, 2021, 13, 656990.	3.4	4
18	Metabolic Syndrome Is Associated With Poor Cognition: A Population-Based Study of 70-Year-Old Adults Without Dementia. Journals of Gerontology - Series A Biological Sciences and Medical Sciences, 2021, 76, 2275-2283.	3.6	20

#	Article	IF	Citations
19	Functional Connectivity and Compensation of Phonemic Fluency in Aging. Frontiers in Aging Neuroscience, 2021, 13, 644611.	3.4	5
20	The Cognitive Connectome in Healthy Aging. Frontiers in Aging Neuroscience, 2021, 13, 694254.	3.4	9
21	The interplay between gray matter and white matter neurodegeneration in subjective cognitive decline. Aging, 2021, 13, 19963-19977.	3.1	10
22	Effects of a Highly Challenging Balance Training Program on Motor Function and Brain Structure in Parkinsonâ€™s Disease. Journal of Parkinson's Disease, 2021, 11, 2057-2071.	2.8	8
23	Assessment of Tau Pathology as Measured by 18F-THK5317 and 18F-Flortaucipir PET and Their Relation to Brain Atrophy and Cognition in Alzheimerâ€™s Disease. Journal of Alzheimer's Disease, 2021, 84, 103-117.	2.6	4
24	Seeing Beyond Your Nose? The Effects of Lifelong Olfactory Sensory Deprivation on Cerebral Audio-visual Integration. Neuroscience, 2021, 472, 1-10.	2.3	5
25	Atrial Fibrillation, Stroke, and Silent Cerebrovascular Disease. Neurology, 2021, 97, e1608-e1619.	1.1	24
26	Cerebrovascular disease, neurodegeneration, and clinical phenotype in dementia with Lewy bodies. Neurobiology of Aging, 2021, 105, 252-261.	3.1	18
27	Deep learning from MRI-derived labels enables automatic brain tissue classification on human brain CT. NeuroImage, 2021, 244, 118606.	4.2	13
28	The diagnostic and prognostic capabilities of plasma biomarkers in Alzheimer's disease. Alzheimer's and Dementia, 2021, 17, 1145-1156.	0.8	174
29	Comparison of Two-Dimensional- and Three-Dimensional-Based U-Net Architectures for Brain Tissue Classification in One-Dimensional Brain CT. Frontiers in Computational Neuroscience, 2021, 15, 785244.	2.1	9
30	Demographic and Clinical Characteristics of Individuals with Mild Cognitive Impairment Related to Grade of Alcohol Consumption. Dementia and Geriatric Cognitive Disorders, 2021, 50, 491-497.	1.5	0
31	Cerebrospinal Fluid Biomarkers, Brain Structural and Cognitive Performances Between Normotensive and Hypertensive Controlled, Uncontrolled and Untreated 70-Year-Old Adults. Frontiers in Aging Neuroscience, 2021, 13, 777475.	3.4	4
32	Does a truly hippocampal sparing subtype of Alzheimerâ€™s disease really exist?. Alzheimer's and Dementia, 2021, 17, .	0.8	1
33	Dementia with Lewy bodies subtypes identified by cluster analysis on structural MRI. Alzheimer's and Dementia, 2021, 17, .	0.8	0
34	The association of Alzheimerâ€™s disease and cerebrovascular disease biomarkers towards the neurodegeneration of the cholinergic pathways. Alzheimer's and Dementia, 2021, 17, .	0.8	0
35	Plasma and cerebrospinal fluid neurofilament light protein concentrations are differentially associated with biomarker evidence of neurodegeneration in a communityâ€based population of 70â€yearâ€olds. Alzheimer's and Dementia, 2021, 17, .	0.8	0
36	Association of deepâ€learningâ€“derived brain computed tomography measures with cognition and bloodâ€based biomarkers of neurodegenerative diseases. Alzheimer's and Dementia, 2021, 17, .	0.8	0

#	Article	IF	Citations
37	Cerebrovascular disease and depressive symptomatology in individuals with subjective cognitive decline: A communityâ€based study. Alzheimer's and Dementia, 2021, 17, .	0.8	0
38	Author Response: Biological Subtypes of Alzheimer Disease: A Systematic Review and Meta-analysis. Neurology, 2021, 96, 238-238.	1.1	2
39	Apathy and anxiety are early markers of Alzheimer's disease. Neurobiology of Aging, 2020, 85, 74-82.	3.1	103
40	Distinct tau PET patterns in atrophyâ€defined subtypes of Alzheimer's disease. Alzheimer's and Dementia, 2020, 16, 335-344.	0.8	73
41	Cerebrospinal fluid progranulin is associated with increased cortical thickness in early stages of Alzheimer's disease. Neurobiology of Aging, 2020, 88, 61-70.	3.1	23
42	The heterogeneous functional architecture of the posteromedial cortex is associated with selective functional connectivity differences in Alzheimer's disease. Human Brain Mapping, 2020, 41, 1557-1572.	3.6	10
43	Î²-Amyloid and tau biomarkers and clinical phenotype in dementia with Lewy bodies. Neurology, 2020, 95, e3257-e3268.	1.1	62
44	Cerebrovascular pathology in Alzheimer's disease: Hopes and gaps. Psychiatry Research - Neuroimaging, 2020, 306, 111184.	1.8	16
45	The combined effect of amyloid-Î² and tau biomarkers on brain atrophy in dementia with Lewy bodies. NeuroImage: Clinical, 2020, 27, 102333.	2.7	22
46	The genetic architecture of human brainstem structures and their involvement in common brain disorders. Nature Communications, 2020, 11, 4016.	12.8	26
47	Cerebrospinal Fluid Metals and the Association with Cerebral Small Vessel Disease. Journal of Alzheimer's Disease, 2020, 78, 1229-1236.	2.6	9
48	Automated brainstem volumetry can aid in the diagnostics of parkinsonian disorders. Parkinsonism and Related Disorders, 2020, 79, 18-25.	2.2	12
49	Evaluation of a Novel Psychological Intervention Tailored for Patients With Early Cognitive Impairment (PIPCI): Study Protocol of a Randomized Controlled Trial. Frontiers in Psychology, 2020, 11, 600841.	2.1	3
50	Sex differences in CSF biomarkers for neurodegeneration and bloodâ€brain barrier integrity. Alzheimer's and Dementia, 2020, 16, e038588.	0.8	0
51	Multimodal imaging reveals human cholinergic system functional and structural integrity in vivo. Alzheimer's and Dementia, 2020, 16, e040763.	0.8	1
52	Subtypes of Alzheimerâ€™s disease and the ATN biomarker scheme. Alzheimer's and Dementia, 2020, 16, e040933.	0.8	0
53	Ultrasensitive blood biomarkers to predict cognitive decline and diagnose Alzheimerâ€™s disease in the absence of AT(N) classification as the reference standard. Alzheimer's and Dementia, 2020, 16, e041808.	0.8	1
54	FDGâ€PET subtypes of Alzheimerâ€™s disease and their association with distinct biomarker profiles and clinical trajectories. Alzheimer's and Dementia, 2020, 16, e042101.	0.8	3

#	Article	IF	Citations
55	Heterogeneity in longitudinal deterioration of white matter microstructural integrity in the population and its implications for cognitive aging. Alzheimer's and Dementia, 2020, 16, e042669.	0.8	0
56	Stage vs subtype hypothesis: A longitudinal MRI study investigating the heterogeneity in AD. Alzheimer's and Dementia, 2020, 16, e042907.	0.8	0
57	Atrial fibrillation and the interaction with stroke in relation to white matter lesion volumes: A populationâ€based study in 70â€yearâ€olds. Alzheimer's and Dementia, 2020, 16, e043296.	0.8	0
58	CTâ€based brain segmentation and volumetry using deep learning methods. Alzheimer's and Dementia, 2020, 16, e045824.	0.8	0
59	Plasmaâ€based biomarkers for AÎ² and tau predict longitudinal brain atrophy in cognitively healthy elderly and in patients with Alzheimerâ€™s disease. Alzheimer's and Dementia, 2020, 16, e046490.	0.8	0
60	The reliability of a deep learning model in external memory clinic MRI data: A multiâ€cohort study. Alzheimer's and Dementia, 2020, 16, e042969.	0.8	0
61	Comparison of subtyping methods for neuroimaging studies in Alzheimerâ€™s disease: a call for harmonization. Brain Communications, 2020, 2, fcaa192.	3.3	24
62	The reliability of a deep learning model in clinical out-of-distribution MRI data: A multicohort study. Medical Image Analysis, 2020, 66, 101714.	11.6	90
63	The cholinergic system in subtypes of Alzheimerâ€™s disease: an in vivo longitudinal MRI study. Alzheimer's Research and Therapy, 2020, 12, 51.	6.2	41
64	Morphological changes in secondary, but not primary, sensory cortex in individuals with life-long olfactory sensory deprivation. NeuroImage, 2020, 218, 117005.	4.2	19
65	Shape Information Improves the Cross-Cohort Performance of Deep Learning-Based Segmentation of the Hippocampus. Frontiers in Neuroscience, 2020, 14, 15.	2.8	16
66	Medial temporal atrophy in preclinical dementia: Visual and automated assessment during six year follow-up. NeuroImage: Clinical, 2020, 27, 102310.	2.7	10
67	The MemClin project: a prospective multi memory clinics study targeting early stages of cognitive impairment. BMC Geriatrics, 2020, 20, 93.	2.7	6
68	Longitudinal degeneration of the basal forebrain predicts subsequent dementia in Parkinson's disease. Neurobiology of Disease, 2020, 139, 104831.	4.4	49
69	Cholinergic white matter pathways make a stronger contribution to attention and memory in normal aging than cerebrovascular health and nucleus basalis of Meynert. NeuroImage, 2020, 211, 116607.	4.2	59
70	Biological subtypes of Alzheimer disease. Neurology, 2020, 94, 436-448.	1.1	210
71	High-resolution PET imaging reveals subtle impairment of the serotonin transporter in an early non-depressed Parkinsonâ€™s disease cohort. European Journal of Nuclear Medicine and Molecular Imaging, 2020, 47, 2407-2416.	6.4	12
72	Cortical microstructural correlates of astrocytosis in autosomal-dominant Alzheimer disease. Neurology, 2020, 94, e2026-e2036.	1.1	42

#	Article	IF	Citations
73	Predicting Fazekas scores from automatic segmentations of white matter signal abnormalities. Aging, 2020, 12, 894-901.	3.1	32
74	Fully bayesian longitudinal unsupervised learning for the assessment and visualization of AD heterogeneity and progression. Aging, 2020, 12, 12622-12647.	3.1	11
75	Cholinergic network disruption in AD subtypes: A study using graph theory. Alzheimer's and Dementia, 2020, 16, e043178.	0.8	0
76	Brain Atrophy Subtypes and the ATN Classification Scheme in Alzheimerâ€™s Disease. Neurodegenerative Diseases, 2020, 20, 153-164.	1.4	6
77	European DLB consortium: diagnostic and prognostic biomarkers in dementia with Lewy bodies, a multicenter international initiative. Neurodegenerative Disease Management, 2019, 9, 247-250.	2.2	18
78	Common brain disorders are associated with heritable patterns of apparent aging of the brain. Nature Neuroscience, 2019, 22, 1617-1623.	14.8	358
79	AVRA: Automatic visual ratings of atrophy from MRI images using recurrent convolutional neural networks. NeuroImage: Clinical, 2019, 23, 101872.	2.7	20
80	Subtypes of Alzheimer's Disease Display Distinct Network Abnormalities Extending Beyond Their Pattern of Brain Atrophy. Frontiers in Neurology, 2019, 10, 524.	2.4	52
81	Cortical thinning in patients with REM sleep behavior disorder is associated with clinical progression. Npj Parkinson's Disease, 2019, 5, 7.	5.3	40
82	The MOPEAD project: Advancing patient engagement for the detection of â€œhiddenâ€•undiagnosed cases of Alzheimer's disease in the community. , 2019, 15, 828-839.		20
83	Mapping of apparent susceptibility yields promising diagnostic separation of progressive supranuclear palsy from other causes of parkinsonism. Scientific Reports, 2019, 9, 6079.	3.3	18
84	Subjective Cognitive Decline Below and Above the Age of 60: A Multivariate Study on Neuroimaging, Cognitive, Clinical, and Demographic Measures. Journal of Alzheimer's Disease, 2019, 68, 295-309.	2.6	36
85	Genetic architecture of subcortical brain structures in 38,851 individuals. Nature Genetics, 2019, 51, 1624-1636.	21.4	192
86	The Gothenburg H70 Birth cohort study 2014â€“16: design, methods and study population. European Journal of Epidemiology, 2019, 34, 191-209.	5.7	89
87	A signature pattern of cortical atrophy in dementia with Lewy bodies: A study on 333 patients from the European DLB consortium. Alzheimer's and Dementia, 2019, 15, 400-409.	0.8	60
88	Brain myoinositol as a potential marker of amyloid-related pathology. Neurology, 2019, 92, e395-e405.	1.1	30
89	Repeatability and reproducibility of FreeSurfer, FSL-SIENAX and SPM brain volumetric measurements and the effect of lesion filling in multiple sclerosis. European Radiology, 2019, 29, 1355-1364.	4.5	93
90	Cognitive compensatory mechanisms in normal aging: a study on verbal fluency and the contribution of other cognitive functions. Aging, 2019, 11, 4090-4106.	3.1	26

#	Article	IF	Citations
91	Amyloid and tau accumulate across distinct spatial networks and are differentially associated with brain connectivity. ELife, 2019, 8, .	6.0	57
92	Heterogeneous patterns of brain atrophy in Alzheimer's disease. Neurobiology of Aging, 2018, 65, 98-108.	3.1	110
93	Altered structural network organization in cognitively normal individuals with amyloid pathology. Neurobiology of Aging, 2018, 64, 15-24.	3.1	30
94	Amyloid Network Topology Characterizes the Progression of Alzheimerâ€™s Disease During the Predementia Stages. Cerebral Cortex, 2018, 28, 340-349.	2.9	28
95	Abnormal Structural Brain Connectome in Individuals with Preclinical Alzheimerâ€™s Disease. Cerebral Cortex, 2018, 28, 3638-3649.	2.9	29
96	Phenotypic variability and neuropsychological findings associated with C9orf72 repeat expansions in a Bulgarian dementia cohort. PLoS ONE, 2018, 13, e0208383.	2.5	5
97	Dual tracer tau PET imaging reveals different molecular targets for 11C-THK5351 and 11C-PBB3 in the Alzheimer brain. European Journal of Nuclear Medicine and Molecular Imaging, 2018, 45, 1605-1617.	6.4	36
98	The contribution of small vessel disease to subtypes of Alzheimer's disease: a study on cerebrospinal fluid and imaging biomarkers. Neurobiology of Aging, 2018, 70, 18-29.	3.1	48
99	Proposal for a hierarchical, multidimensional, and multivariate approach to investigate cognitive aging. Neurobiology of Aging, 2018, 71, 179-188.	3.1	23
100	Reduced penetrance of the PSEN1 H163Y autosomal dominant Alzheimer mutation: a 22-year follow-up study. Alzheimer's Research and Therapy, 2018, 10, 45.	6.2	11
101	Stability of graph theoretical measures in structural brain networks in Alzheimerâ€™s disease. Scientific Reports, 2018, 8, 11592.	3.3	41
102	The A/T/N biomarker scheme and patterns of brain atrophy assessed in mild cognitive impairment. Scientific Reports, 2018, 8, 8431.	3.3	55
103	Differential Associations of IL-4 With Hippocampal Subfields in Mild Cognitive Impairment and Alzheimerâ€™s Disease. Frontiers in Aging Neuroscience, 2018, 10, 439.	3.4	21
104	The heterogeneity within Alzheimer's disease. Aging, 2018, 10, 3058-3060.	3.1	41
105	Novel genetic loci associated with hippocampal volume. Nature Communications, 2017, 8, 13624.	12.8	250
106	27-Hydroxycholesterol impairs neuronal glucose uptake through an IRAP/GLUT4 system dysregulation. Journal of Experimental Medicine, 2017, 214, 699-717.	8.5	64
107	The interactive effect of demographic and clinical factors on hippocampal volume: A multicohort study on 1958 cognitively normal individuals. Hippocampus, 2017, 27, 653-667.	1.9	20
108	Reproducible segmentation of white matter hyperintensities using a new statistical definition. Magnetic Resonance Materials in Physics, Biology, and Medicine, 2017, 30, 227-237.	2.0	10

#	Article	IF	Citations
109	Distinct subtypes of Alzheimerâ€™s disease based on patterns of brain atrophy: longitudinal trajectories and clinical applications. Scientific Reports, 2017, 7, 46263.	3.3	141
110	Association between cerebrospinal fluid and plasma neurodegeneration biomarkers with brain atrophy in Alzheimer's disease. Neurobiology of Aging, 2017, 58, 14-29.	3.1	93
111	A â€˜Disease Severity Indexâ€™ to identify individuals with Subjective Memory Decline who will progress to mild cognitive impairment or dementia. Scientific Reports, 2017, 7, 44368.	3.3	23
112	The Effects of Gene Mutations onÂDefaultÂMode Network inÂFamilialÂAlzheimerâ€™s Disease. Journal of Alzheimer's Disease, 2017, 56, 327-334.	2.6	8
113	Imaging biomarkers of dementia: recommended visual rating scales with teaching cases. Insights Into Imaging, 2017, 8, 79-90.	3.4	67
114	Monitoring disease progression in mild cognitive impairment: Associations between atrophy patterns, cognition, APOE and amyloid. NeuroImage: Clinical, 2017, 16, 418-428.	2.7	23
115	Quantitative susceptibility mapping differentiates between parkinsonian disorders. Parkinsonism and Related Disorders, 2017, 44, 51-57.	2.2	77
116	The Evansâ€™ Index revisited: New cut-off levels for use in radiological assessment of ventricular enlargement in the elderly. European Journal of Radiology, 2017, 95, 28-32.	2.6	84
117	[F1â€“02â€“02]: DISCOVERY AND VALIDATION OF MULTIMODAL BIOMARKER SIGNATURES RELATING TO ALZHEIMER'S DISEASE PATHOLOGY AND PROGRESSION. Alzheimer's and Dementia, 2017, 13, P174.	0.8	0
118	Cognitive Variability during Middle-Age: Possible Association with Neurodegeneration and Cognitive Reserve. Frontiers in Aging Neuroscience, 2017, 9, 188.	3.4	50
119	Atrophy of the Posterior Subiculum Is Associated with Memory Impairment, Tau- and AÎ² Pathology in Non-demented Individuals. Frontiers in Aging Neuroscience, 2017, 9, 306.	3.4	30
120	Clinical utility and research frontiers of neuroimaging in movement disorders. Quarterly Journal of Nuclear Medicine and Molecular Imaging, 2017, 61, 372-385.	0.7	3
121	BRAPH: A graph theory software for the analysis of brain connectivity. PLoS ONE, 2017, 12, e0178798.	2.5	187
122	A Multi-Cohort Study of ApoE É›4 and Amyloid-Î² Effects on the Hippocampus in Alzheimerâ€™s Disease. Journal of Alzheimer's Disease, 2017, 56, 1159-1174.	2.6	36
123	MRI-assessed atrophy subtypes in Alzheimerâ€™s disease and the cognitive reserve hypothesis. PLoS ONE, 2017, 12, e0186595.	2.5	51
124	Targeted delivery of nerve growth factor to the cholinergic basal forebrain of Alzheimerâ€™s disease patients: application of a second-generation encapsulated cell biodelivery device. Alzheimer's Research and Therapy, 2016, 8, 30.	6.2	110
125	Cerebrospinal Fluid Biomarkers for the Differential Diagnosis between Alzheimerâ€™s Disease and Frontotemporal Lobar Degeneration: Systematic Review, HSROC Analysis, and Confounding Factors. Journal of Alzheimer's Disease, 2016, 55, 625-644.	2.6	44
126	The Effect of Age Correction on Multivariate Classification in Alzheimerâ€™s Disease, with a Focus on the Characteristics of Incorrectly and Correctly Classified Subjects. Brain Topography, 2016, 29, 296-307.	1.8	44

#	Article	IF	Citations
127	Myo-inositol changes precede amyloid pathology and relate to APOE genotype in Alzheimer disease. Neurology, 2016, 86, 1754-1761.	1.1	66
128	Novel genetic loci underlying human intracranial volume identified through genome-wide association. Nature Neuroscience, 2016, 19, 1569-1582.	14.8	213
129	Different reserve proxies confer overlapping and unique endurance to cortical thinning in healthy middle-aged adults. Behavioural Brain Research, 2016, 311, 375-383.	2.2	36
130	Volumetric MRI as a Diagnostic Tool in Alzheimerâ€™s Disease. Methods in Pharmacology and Toxicology, 2016, , 181-198.	0.2	3
131	Disrupted Network Topology in Patients with Stable and Progressive Mild Cognitive Impairment and Alzheimer's Disease. Cerebral Cortex, 2016, 26, 3476-3493.	2.9	110
132	Quantitative validation of a visual rating scale for frontal atrophy: associations with clinical status, APOE e4, CSF biomarkers and cognition. European Radiology, 2016, 26, 2597-2610.	4.5	39
133	Measuring Global Brain Atrophy with the Brain Volume/Cerebrospinal Fluid Index: Normative Values, Cut-Offs and Clinical Associations. Neurodegenerative Diseases, 2016, 16, 77-86.	1.4	29
134	The effect of increased genetic risk for Alzheimer's disease on hippocampal and amygdala volume. Neurobiology of Aging, 2016, 40, 68-77.	3.1	115
135	Manual Planimetry of the Medial Temporal Lobe Versus Automated Volumetry of the Hippocampus in the Diagnosis of Alzheimer's Disease. Cureus, 2016, 8, e544.	0.5	10
136	Early astrocytosis in autosomal dominant Alzheimerâ€™s disease measured in vivo by multi-tracer positron emission tomography. Scientific Reports, 2015, 5, 16404.	3.3	110
137	Tract Based Spatial Statistic Reveals No Differences in White Matter Microstructural Organization between Carriers and Non-Carriers of the APOE É›4 and É›2 Alleles in Young Healthy Adolescents. Journal of Alzheimer's Disease, 2015, 47, 977-984.	2.6	17
138	Linking Genetics of Brain Changes to Alzheimer's Disease: Sparse Whole Genome Association Scan of Regional MRI Volumes in the ADNI and AddNeuroMed Cohorts. Journal of Alzheimer's Disease, 2015, 45, 851-864.	2.6	10
139	Common genetic variants influence human subcortical brain structures. Nature, 2015, 520, 224-229.	27.8	772
140	Medial Temporal Lobe Atrophy and Depressive Symptoms in Elderly Patients With and Without Alzheimer Disease. Journal of Geriatric Psychiatry and Neurology, 2015, 28, 40-48.	2.3	22
141	Changes in CSF cholinergic biomarkers in response to cell therapy with NGF in patients with Alzheimer's disease. Alzheimer's and Dementia, 2015, 11, 1316-1328.	0.8	50
142	Alterations in brain leptin signalling in spite of unchanged <scp>CSF</scp> leptin levels in Alzheimer's disease. Aging Cell, 2015, 14, 122-129.	6.7	56
143	Automated CT-based segmentation and quantification of total intracranial volume. European Radiology, 2015, 25, 3151-3160.	4.5	17
144	Automated Hippocampal Subfield Measures as Predictors of Conversion from Mild Cognitive Impairment to Alzheimerâ€™s Disease in Two Independent Cohorts. Brain Topography, 2015, 28, 746-759.	1.8	69

#	Article	IF	Citations
145	Aberrant cerebral network topology and mild cognitive impairment in early Parkinson's disease. Human Brain Mapping, 2015, 36, 2980-2995.	3.6	87
146	A Subset of Cerebrospinal Fluid Proteins from a Multi-Analyte Panel Associated with Brain Atrophy, Disease Classification and Prediction in Alzheimerâ€™s Disease. PLoS ONE, 2015, 10, e0134368.	2.5	26
147	Predicting Progression of Alzheimerâ€™s Disease Using Ordinal Regression. PLoS ONE, 2014, 9, e105542.	2.5	44
148	Meta-Review of CSF Core Biomarkers in AlzheimerÃ¢â‚¬â„¢s Disease: The State-of-the-Art after the New Revised Diagnostic Criteria. Frontiers in Aging Neuroscience, 2014, 6, 47.	3.4	105
149	Application of a MRI based index to longitudinal atrophy change in Alzheimer disease, mild cognitive impairment and healthy older individuals in the AddNeuroMed cohort. Frontiers in Aging Neuroscience, 2014, 6, 145.	3.4	29
150	The effects of intracranial volume adjustment approaches on multiple regional MRI volumes in healthy aging and Alzheimer's disease. Frontiers in Aging Neuroscience, 2014, 6, 264.	3.4	322
151	TheHiveDB image data management and analysis framework. Frontiers in Neuroinformatics, 2014, 7, 49.	2.5	82
152	Large-scale resting state network correlates of cognitive impairment in Parkinson's disease and related dopaminergic deficits. Frontiers in Systems Neuroscience, 2014, 8, 45.	2.5	90
153	Influence of age, disease onset and ApoE4 on visual medial temporal lobe atrophy cutâ€offs. Journal of Internal Medicine, 2014, 275, 317-330.	6.0	60
154	Cortical Changes Associated with Depression and Antidepressant Use in Alzheimer and Lewy Body Dementia: An MRI Surface-based Morphometric Study. American Journal of Geriatric Psychiatry, 2014, 22, 4-13.e1.	1.2	41
155	Regional vulnerability of hippocampal subfields to aging measured by structural and diffusion MRI. Hippocampus, 2014, 24, 403-414.	1.9	67
156	Structural brain changes associated with depressive symptoms in the elderly with Alzheimer's disease. Journal of Neurology, Neurosurgery and Psychiatry, 2014, 85, 930-935.	1.9	53
157	Plasma proteins predict conversion to dementia from prodromal disease. Alzheimer's and Dementia, 2014, 10, 799.	0.8	180
158	No Differences in Hippocampal Volume between Carriers and Non-Carriers of the ApoE Îµ4 and Îµ2 Alleles in Young Healthy Adolescents. Journal of Alzheimer's Disease, 2014, 40, 37-43.	2.6	51
159	Multiple sclerosis patients lacking oligoclonal bands in the cerebrospinal fluid have less global and regional brain atrophy. Journal of Neuroimmunology, 2014, 274, 149-154.	2.3	48
160	Alzheimer's disease biomarker discovery using SOMAscan multiplexed protein technology. Alzheimer's and Dementia, 2014, 10, 724-734.	0.8	182
161	Cognitive decline is mediated by gray matter changes during middle age. Neurobiology of Aging, 2014, 35, 1086-1094.	3.1	48
162	Initial cognitive decline is associated with cortical thinning in early Parkinson disease. Neurology, 2014, 82, 2017-2025.	1.1	158

#	Article	IF	Citations
163	Multivariate Data Analysis and Machine Learning in Alzheimer's Disease with a Focus on Structural Magnetic Resonance Imaging. Journal of Alzheimer's Disease, 2014, 41, 685-708.	2.6	165
164	Brain Changes in Alzheimer's Disease Patients with Implanted Encapsulated Cells Releasing Nerve Growth Factor. Journal of Alzheimer's Disease, 2014, 43, 1059-1072.	2.6	71
165	Improving CSF BiomarkersÃ¢â‚¬â„¢ Performance for Predicting Progression from Mild Cognitive Impairment to AlzheimerÃ¢â‚¬â„¢s Disease by Considering Different Confounding Factors: A Meta-Analysis. Frontiers in Aging Neuroscience, 2014, 6, 287.	3.4	44
166	Preclinical Cerebrospinal Fluid and Volumetric Magnetic Resonance Imaging Biomarkers in Swedish Familial Alzheimer's Disease. Journal of Alzheimer's Disease, 2014, 43, 1393-1402.	2.6	26
167	Candidate Blood Proteome Markers of Alzheimer's Disease Onset and Progression: A Systematic Review and Replication Study. Journal of Alzheimer's Disease, 2013, 38, 515-531.	2.6	160
168	Different multivariate techniques for automated classification of MRI data in Alzheimerâ€™s disease and mild cognitive impairment. Psychiatry Research - Neuroimaging, 2013, 212, 89-98.	1.8	98
169	Regional Magnetic Resonance Imaging Measures for Multivariate Analysis in Alzheimerâ€™s Disease and Mild Cognitive Impairment. Brain Topography, 2013, 26, 9-23.	1.8	174
170	Entorhinal Cortex Thickness Predicts Cognitive Decline in Alzheimer's Disease. Journal of Alzheimer's Disease, 2013, 33, 755-766.	2.6	105
171	Ratio of AÎ²42/P-tau181p in CSF is associated with aberrant default mode network in AD. Scientific Reports, 2013, 3, 1339.	3.3	39
172	Demography, diagnostics, and medication in dementia with Lewy bodies and Parkinson's disease with dementia: data from the Swedish Dementia Quality Registry (SveDem). Neuropsychiatric Disease and Treatment, 2013, 9, 927.	2.2	33
173	Cognitive impairment in patients with Parkinson's disease: diagnosis, biomarkers, and treatment. Lancet Neurology, The, 2012, 11, 697-707.	10.2	432
174	Combining MRI and CSF measures for classification of Alzheimer's disease and prediction of mild cognitive impairment conversion. NeuroImage, 2012, 62, 229-238.	4.2	275
175	Multispectral MRI segmentation of age related white matter changes using a cascade of support vector machines. Journal of the Neurological Sciences, 2012, 322, 211-216.	0.6	44
176	Education increases reserve against Alzheimerâ€™s diseaseâ€”evidence from structural MRI analysis. Neuroradiology, 2012, 54, 929-938.	2.2	148
177	Plasma Based Markers of [11C] PiB-PET Brain Amyloid Burden. PLoS ONE, 2012, 7, e44260.	2.5	89
178	Is the subcallosal medial prefrontal cortex a common site of atrophy in Alzheimer's disease and frontotemporal lobar degeneration?. Frontiers in Aging Neuroscience, 2012, 4, 32.	3.4	15
179	AddNeuroMed and ADNI: Similar patterns of Alzheimer's atrophy and automated MRI classification accuracy in Europe and North America. NeuroImage, 2011, 58, 818-828.	4.2	121
180	Multivariate analysis of MRI data for Alzheimer's disease, mild cognitive impairment and healthy controls. NeuroImage, 2011, 54, 1178-1187.	4.2	128

#	Article	IF	Citations
181	Combination analysis of neuropsychological tests and structural MRI measures in differentiating AD, MCI and control groupsâ€"The AddNeuroMed study. Neurobiology of Aging, 2011, 32, 1198-1206.	3.1	69
182	Glucose metabolism and PIB binding in carriers of a His163Tyr presenilin 1 mutation. Neurobiology of Aging, 2011, 32, 1388-1399.	3.1	48
183	Magnetic Resonance Imaging and Magnetic Resonance Spectroscopy for Detection of Early Alzheimer's Disease. Journal of Alzheimer's Disease, 2011, 26, 307-319.	2.6	26
184	Sensitivity and Specificity of Medial Temporal Lobe Visual Ratings and Multivariate Regional MRI Classification in Alzheimer's Disease. PLoS ONE, 2011, 6, e22506.	2.5	103
185	Plasma Biomarkers of Brain Atrophy in Alzheimer's Disease. PLoS ONE, 2011, 6, e28527.	2.5	106
186	1H-MRS in spinal cord injury: acute and chronic metabolite alterations in rat brain and lumbar spinal cord. European Journal of Neuroscience, 2011, 33, 678-688.	2.6	20
187	The AddNeuroMed framework for multiâ€centre MRI assessment of Alzheimer's disease : experience from the first 24 months. International Journal of Geriatric Psychiatry, 2011, 26, 75-82.	2.7	127
188	Combining MRI and MRS to Distinguish Between Alzheimer's Disease and Healthy Controls. Journal of Alzheimer's Disease, 2010, 22, 171-181.	2.6	30
189	Effect of APOE Îµ4 Allele on Cortical Thicknesses and Volumes: The AddNeuroMed Study. Journal of Alzheimer's Disease, 2010, 21, 947-966.	2.6	82
190	APOE ε2 Allele Is Associated with Larger Regional Cortical Thicknesses and Volumes. Dementia and Geriatric Cognitive Disorders, 2010, 30, 229-237.	1.5	40
191	Association of Plasma Clusterin Concentration With Severity, Pathology, and Progression in Alzheimer Disease. Archives of General Psychiatry, 2010, 67, 739.	12.3	353
192	Analysis of regional MRI volumes and thicknesses as predictors of conversion from mild cognitive impairment to Alzheimer's disease. Neurobiology of Aging, 2010, 31, 1375-1385.	3.1	104
193	In vivo 1H-magnetic resonance spectroscopy can detect metabolic changes in APP/PS1 mice after donepezil treatment. BMC Neuroscience, 2009, 10, 33.	1.9	33
194	MRI Measures of Alzheimer's Disease and the AddNeuroMed Study. Annals of the New York Academy of Sciences, 2009, 1180, 47-55.	3.8	121
195	Age related changes in brain metabolites observed by 1H MRS in APP/PS1 mice. Neurobiology of Aging, 2008, 29, 1423-1433.	3.1	97
196	Reorganization of sensory processing below the level of spinal cord injury as revealed by fMRI. Experimental Neurology, 2008, 209, 155-160.	4.1	40
197	Kv1.1 null mice have enlarged hippocampus and ventral cortex. BMC Neuroscience, 2007, 8, 10.	1.9	19
198	Carbamazepine treatment recovered low N-acetylaspartate+N-acetylaspartylglutamate (tNAA) levels in the megencephaly mouse BALB/cByJ-Kv1.1mceph/mceph. Neurobiology of Disease, 2007, 26, 221-228.	4.4	18

#	Article	IF	Citations
199	Blood Oxygenation Level-Dependent Visualization of Synaptic Relay Stations of Sensory Pathways along the Neuroaxis in Response to Graded Sensory Stimulation of a Limb. Journal of Neuroscience, 2006, 26, 6330-6336.	3.6	84
200	Stage vs. Subtype Hypothesis in Alzheimer's Disease: A Multi-Cohort and Longitudinal Bayesian Clustering Study. SSRN Electronic Journal, 0, , .	0.4	2